الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 187 |  |  |
| | | from | 187 | | |
Abstract
In patients presenting with ST-segment elevation myocardial infarction (STEMI), primary percutaneous coronary intervention (PCI) reduces ischemic complications and improves survival, when compared with pharmacologic reperfusion with fibrinolytic agents. (Keeley et al., 2003).
Patients undergoing primary PCI, however, are at high risk of contrast-induced nephropathy (CIN), a complication that has a serious impact on in-hospital outcome and may partially affect the overall benefit of primary PCI. Indeed, in-hospital mortality has been shown to be 20 times higher in patients who experience CIN after primary PCI as compared with those without this complication (Marenzi et al., 2009). Contrast-induced nephropathy is defined as impairment of renal function occurring within 48 hours after administration of contrast medium. It’s manifested by an increase in serum creatinine level of 0.5 mg/dl or by a relative increase of 25% over the baseline value (McCullough et al., 2006). Among many inflammatory markers, high-sensitivity C-reactive protein (hs-CRP) is the most extensively studied biomarker of inflammation in cardiovascular disease (Roberts WL et al 2001) The results from many studies have shown a significant association between the elevated plasma level of hs-CRP and the severity of atherosclerosis, the incidence of cardiovascular events in individuals with risk factors, and the risk of recurrent cardiovascular events among patients with established coronary heart disease.(ZachoJ et al 2008) The role of hs-CRP as a predictor of the prognosis of cardiovascular disease has also been studied by many.